Inclisiran

Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity

Retrieved on: 
Thursday, November 2, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, FDA, ATTR, The New England Journal of Medicine, Science, Therapy, Bachelor of Medicine, Bachelor of Surgery, Cardiomyopathy, Medication, Use, Viral hepatitis, Symantec Endpoint Protection, Conference, American Heart Association, Quarter, Acquisition, Haemophilia, Clinical trial, TTR, Truly Madly Deeply – Ultra Rare Tracks, Growth, Polyneuropathy, Risk, Hypertension, RNA interference, ALN, Roche, Sanofi, Amyloidosis, Patient, APOLLO, ASCVD, Phase 1, Pharmaceutical industry, Video game, Medical device, Aluminium, Regeneron Pharmaceuticals, Alnylam Pharmaceuticals, Inclisiran

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2023 and reviewed recent business highlights.

Key Points: 
  • Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2023 and reviewed recent business highlights.
  • Attained over 3,790 hATTR amyloidosis patients with polyneuropathy worldwide on commercial treatment with ONPATTRO or AMVUTTRA as of September 30, 2023.
  • Alnylam announces today that it will present a review of its RNAi platform and pipeline progress at a virtual R&D Day on December 13, 2023.
  • Financial Results for the Quarter Ended September 30, 2023

Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity

Retrieved on: 
Thursday, May 4, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, HTRS, CHDI, Bachelor of Medicine, Bachelor of Surgery, Patisiran, PEG, Haemophilia, APOLLO, Acquisition, Patient, RNA interference, Cardiomyopathy, Brazilian Health Regulatory Agency, Polyneuropathy, The Lancet, Tissue, Therapy, NASH, Quarter, Corporate social responsibility, Brain, Medication, Randomness, Corporation, Liver, Growth, Innovation, Lancet, Viral hepatitis, Conference, Eos, Safety, ANVISA, Workplace, AHP, Hepatitis B virus, Truly Madly Deeply – Ultra Rare Tracks, Gene silencing, Shanda, Sanofi, HBV, Central nervous system, CER, Regeneron Pharmaceuticals, RTE, SAD, CNS, Peripheral nervous system, TTR, ATTR, Amyloidosis, Hemostasis, Pharmaceutical industry, Vaccine, Management, Cryptocurrency, Inclisiran, Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2023 and reviewed recent business highlights.

Key Points: 
  • Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2023 and reviewed recent business highlights.
  • Attained over 3,160 hATTR amyloidosis patients with polyneuropathy worldwide on commercial treatment with ONPATTRO or AMVUTTRA as of March 31, 2023.
  • Alnylam announces today that it intends to present 18-month results from the APOLLO-B Phase 3 study of patisiran at ESC-HF 2023, being held May 20-23, 2023 in Prague.
  • Financial Results for the Quarter Ended March 31, 2023

Non-Viral / Intracellular Drug Delivery Systems Global Market Report 2022: Sector Gains Traction with Over 20,000 Studies Currently Ongoing Worldwide - ResearchAndMarkets.com

Retrieved on: 
Friday, January 13, 2023
Biotechnology, Pharmaceutical, Genetics, Health, Molecule, Genome, Juno, Toxicity, CPP, Virus, Juno Therapeutics, DNA, Peptide, Novartis, Administration, Type, LDL, Sirna, Partnership, Proteome, Growth, Therapy, Cell membrane, Payment, Enzyme, Exosome, USFDA, Cell biology, Cytoplasm, Vaccine, Pharmaceutical industry, Fine chemical, Inclisiran

In recent years, efficient methods for facilitation of intracellular drug delivery have become a prominent need within the modern biopharmaceutical industry.

Key Points: 
  • In recent years, efficient methods for facilitation of intracellular drug delivery have become a prominent need within the modern biopharmaceutical industry.
  • Specifically, viral drug delivery systems utilize the ability of viruses to inject their DNA inside host cells.
  • How is the intellectual property landscape related to intracellular drug delivery likely to evolve in the foreseen future?
  • How is the current and future market opportunity likely to be distributed across key market segments and geographical region?

Terray Therapeutics Appoints John Maraganore, Ph.D., as Strategic Advisor

Retrieved on: 
Tuesday, December 13, 2022
Biotechnology, Therapy, Senior advisor, Chicago (franchise), RNA interference, Norwest Venture Partners, Atlas Venture, Drug discovery, Automation, Patient, Science, Research, Biology, AI, Molecular biology, VC, Investment, Multimedia, Nanotechnology, University, Eye, Biochemistry, Partner, RNA, Management, Pharmaceutical industry, Alnylam Pharmaceuticals, Inclisiran, Lionel Terray

PASADENA, Calif., Dec. 13, 2022 /PRNewswire/ -- Terray Therapeutics, a biotechnology company accelerating drug discovery through the application of computational approaches to precisely generated chemical data at scale, today announced that John Maraganore, Ph.D., former founding CEO of Alnylam Pharmaceuticals, has been appointed as Strategic Advisor to the Board of Directors and Leadership Team.

Key Points: 
  • "We are thrilled to welcome John to the Terray team," said Jacob Berlin, Ph.D., Chief Executive Officer of Terray.
  • I welcome his experience and guidance to Terray as we continue bridging the gap between discovery and treatment."
  • "I am a firm believer in the power of insight-driven platforms to deliver sustainable innovation," said John Maraganore.
  • Terray Therapeutics is a biotechnology company operating at the convergence of AI, biology, medicinal chemistry, automation, and nanotechnology to propel drug discovery into the information age.

GNS Appoints John Maraganore as Chair of the Board

Retrieved on: 
Thursday, November 3, 2022
Board, Chicago (franchise), RNA interference, Takeda Oncology, Patient, Chairperson, HIV disease progression rates, Investment, Neurology, Norwest Venture Partners, Agios Pharmaceuticals, University, Neurodegeneration, Molecular biology, GNS, Social media, Upjohn, Senior advisor, AI, M&A, Growth, Biogen, BIO, Biotechnology Innovation Organization, CEO, Advisory board, Research, Leadership, Digital twin, ZymoGenetics, RNA, Atlas Venture, Takeda Pharmaceutical Company, Industry, Nucleation, Therapy, Director, Partner, Business, The Advisory Board Company, Degenerative disease, Biochemistry, Pharmaceutical industry, Alnylam Pharmaceuticals, Inclisiran

Maraganore, who became a strategic advisor to GNS in June 2022 succeeds Timothy Thompson, who served as Executive Chair since 2020.

Key Points: 
  • Maraganore, who became a strategic advisor to GNS in June 2022 succeeds Timothy Thompson, who served as Executive Chair since 2020.
  • From his roles at Biogen to Millennium Pharmaceuticals to Alnylam, John is the rare individual who has brought innovation to market.
  • "I would like also to thank our outgoing Board Chair, Timothy Thompson, who will remain on the board, for his dedication and valuable service to GNS."
  • Dr. Maraganore is Chair Emeritus and a member of the Board of the Biotechnology Innovation Organization (BIO), where he was Chair from 2017-2019.

GNS Appoints John Maraganore, PhD, as Strategic Advisor

Retrieved on: 
Thursday, June 9, 2022
Leadership, GNS, Upjohn, Lists of diseases, Research, Molecular biology, Advisory board, Doctor of Philosophy, HIV disease progression rates, Business, Partner, Atlas Venture, Colin, RNA interference, CEO, RNA, AI, Investment, University, Therapy, Terra Venture Partners, Patient, Neurology, ZymoGenetics, The Advisory Board Company, Biotechnology Innovation Organization, Biogen, Board, Drug discovery, Gemini, M&A, Biochemistry, Chicago (franchise), Pharmaceutical industry, Alnylam Pharmaceuticals, Inclisiran

SOMERVILLE, Mass., June 9, 2022 /PRNewswire/ -- GNS today announced that John Maraganore, PhD, biopharma industry leader and the former founding CEO of Alnylam Pharmaceuticals, has joined GNS as a strategic advisor.

Key Points: 
  • SOMERVILLE, Mass., June 9, 2022 /PRNewswire/ -- GNS today announced that John Maraganore, PhD, biopharma industry leader and the former founding CEO of Alnylam Pharmaceuticals, has joined GNS as a strategic advisor.
  • "John is a visionary and an inspiration for the biopharma industry and hisperspective and deep insights in life sciences R&D will be incredibly valuable for GNS.
  • "GNS is in a unique position to radically transform drug discovery and development", said Dr. Maraganore.
  • GNS' partners include seven out of the top ten pharmaceutical companies, leading research centers, medical societies, and patient advocacy groups globally.

Leqvio® Therapy to Lower Cholesterol Approved by FDA, IVX Health Now Accepting New Leqvio Patients

Retrieved on: 
Tuesday, February 8, 2022
IVX, Wi-Fi, Multimedia, Crohn's disease, Multiple sclerosis, Cholesterol, Rheumatoid arthritis, FDA, Patient, Adult, Novartis, Health, Degenerative disease, View, Pharmaceutical industry, Medicine, Health insurance, Inclisiran

IVX Health is currently accepting referrals for Leqvio patients in its over 50 infusion centers across the nation.

Key Points: 
  • IVX Health is currently accepting referrals for Leqvio patients in its over 50 infusion centers across the nation.
  • Leqvio is a health care practitioner-administered drug, requiring patients to receive treatments from a clinical professional such as a registered nurse.
  • With IVX Health, patients whose treatment plan includes Leqvio now have a convenient, safe, and private place to receive ongoing Leqvio injections.
  • IVX Health is now accepting new Leqvio patients.

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional Updates

Retrieved on: 
Sunday, January 9, 2022
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Gene silencing, Physiology, Safety, COVID-19, RNA transfection, Novartis, Government, Polyneuropathy, Growth, Therapy, Inclisiran, Nobel Prize, Company, Private Securities Litigation Reform Act, Patient, Adult, Sirna, Cell, TTR, Goal, Science, Nobel Prize in Physiology or Medicine, Central nervous system, Intellectual property, Conference, U.S. Securities and Exchange Commission, Twitter, Medication, Security (finance), RNA interference, Disease, SEC, LinkedIn, Marketing, Instagram, Regeneron Pharmaceuticals, RNA, CNS, Biology, Risk, Drug development, Nasdaq, Bachelor of Medicine, Bachelor of Surgery, Pharmaceutical industry, Lithium, Medical device, Online gambling, Medicine, Alnylam Pharmaceuticals, RNAi Therapeutics, Alnylam Pharmaceuticals, RNAI THERAPEUTICS, ALNYLAM PHARMACEUTICALS

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2021 global net product revenues for ONPATTRO, GIVLAARI and OXLUMO and provided additional updates on the products commercial launches.

Key Points: 
  • Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2021 global net product revenues for ONPATTRO, GIVLAARI and OXLUMO and provided additional updates on the products commercial launches.
  • Preliminary global net product revenues for the fourth quarter and full year 2021 were approximately $139 million and $475 million, respectively, representing quarterly and annual growth of 15% and 55% compared to Q3 2021 and full year 2020, respectively.
  • Preliminary global net product revenues for the fourth quarter and full year 2021 were approximately $41 million and $128 million, respectively, representing quarterly and annual growth of 28% and 132% compared to Q3 2021 and full year 2020, respectively.
  • Preliminary global net product revenues for the fourth quarter and full year 2021 were approximately $19 million and $60 million, respectively, representing quarterly growth of 29% compared to Q3 2021.

RTW Investments Bolsters Leadership Team With Key Executive Appointments

Retrieved on: 
Thursday, January 6, 2022
Professional Services, Health, Other Health, Finance, Pharmaceutical, Biotechnology, Molecular biology, Therapy, BIO, Strategic planning, ZymoGenetics, University, ASO, Doctor of Philosophy, Patient, RTW, Head, Business, Atlas, Memorial Sloan Kettering Cancer Center, Genentech, CEO, Biochemistry, Upjohn, Partnership, Board, Atlas Venture, Master of Science, RNA interference, Chicago (franchise), Industry, Biotechnology Innovation Organization, Leadership, Investment, Management, Fine chemical, Science, Inclisiran, Biogen, Alnylam Pharmaceuticals

We have a long-standing relationship starting with our early investment in John and his team at Alnylam.

Key Points: 
  • We have a long-standing relationship starting with our early investment in John and his team at Alnylam.
  • His ability to identify great science and develop a world-class management team fits perfectly with what were building here at RTW, said Roderick Wong, M.D., managing partner and chief investment officer.
  • As an executive partner at RTW, he will help bolster the firms expertise in next generation of technologies and treatment modalities.
  • In addition to his role as executive partner at RTW Investments, Dr. Maraganore serves as venture partner at ARCH Venture Partners and as a venture advisor for Atlas Ventures.

Alnylam Comments on FDA Approval of Leqvio®, the First siRNA (RNAi Therapeutic) Approved to Reduce LDL-C

Retrieved on: 
Wednesday, December 22, 2021
FDA, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Mortality, Sequah Medicine Company, Nobel Prize, Disease, Lists of diseases, LinkedIn, Cell, CNS, Twitter, Sirna, Private Securities Litigation Reform Act, Intellectual property, COVID-19, Regeneron Pharmaceuticals, Physiology, European Medicines Agency, Food, U.S. Securities and Exchange Commission, Drug development, RNA, Biology, Risk, Patient, Nobel Prize in Physiology or Medicine, RNA interference, Diet, Government, Polyneuropathy, LDL, SEC, ESC, Science, Goal, Marketing, Instagram, Therapy, Central nervous system, Safety, Security (finance), RNA transfection, Medication, Novartis, Nasdaq, FDA, Blackstone, Growth, ORION, EMA, Gene silencing, Pharmaceutical industry, Alnylam Pharmaceuticals, Medicine, Inclisiran

Leqvio is the fourth Alnylam-discovered medicine using its RNAi therapeutic platform to be approved to date.

Key Points: 
  • Leqvio is the fourth Alnylam-discovered medicine using its RNAi therapeutic platform to be approved to date.
  • The Leqvio approval marks the first U.S. approval of an RNAi therapeutic indicated to treat a major risk factor for a highly prevalent disease.
  • Alnylam launched its first RNAi therapeutic in 2018 with the FDA approval of ONPATTRO (patisiran) for treatment of the polyneuropathy caused by hATTR amyloidosis, a progressive and life-threatening, rare, genetic disease.
  • The approval of Leqvio, a potentially transformational medicine for lowering LDL-C is a historic event for Alnylam and its RNAi therapeutics platform.